IACP Talks to the Media About the Passage of HR 3204
IACP and its media team spent a considerable amount of time interviewing with the media upon the passage of HR 3204 - continuing to voice our opinion that the provisions of 3204 do not in fact protect the American public.
Click here to view IACP's Official Statement on HR 3204
We were successful in disseminating this message to several high-profile news outlets. David G. Miller, RPh, IACP CEO, is featured in an ABC News story, "Compounding Pharmacy Bill Might Not Make Drugs Safer."
Says Miller, "I think the FDA realizes its own failure to act swiftly in the NECC case and that has elevated their scrutiny of compounding pharmacies to the point where [they] cannot -- [they] do not want to be put in the position of being accused of not taking swift action." Click here to read the ABC News story.
Additional stories: Boston Globe; New York Times; Baltimore Sun
IACP Sends Letter to the Editor at More Magazine
IACP's phones, faxes and emails literally lit up once the October 2013 edition of More Magazine hit the internet. "The Hormone Hoax Thousands Fall For" article got our members' and patients' blood boiling as well it should. One of IACP's primary goals has been to generate proactive media relations. We also believe it’s important to generate Letters to the Editor when we believe a media outlet has just plain got it wrong. Such is the case with More Magazine and its erroneous statements on bio-identical hormone replacement (BHRT). Click here to read the More Magazine article.
IACP's David Miller, CEO, says in his letter to the publication, "Your October 2013 article “The Hormone Hoax Thousands Fall For” contains some valuable information about how careful women should be with hormones or anything they put into their bodies. But by raising the specter of the New England Compounding Center tragedy so far out of context, you unfairly denigrate the pharmacists who provide vital medicine to countless women suffering from the debilitating symptoms of perimenopause and menopause. Many parts of the article read like marketing material for the Food and Drug Administration and the commercial drug manufacturing industry." Click here to read the entire letter.